search
Back to results

Fecal Microbiota Transplantation in Patients With Irritable Bowel Syndrome

Primary Purpose

Irritable Bowel Syndrome (IBS)

Status
Completed
Phase
Not Applicable
Locations
Sweden
Study Type
Interventional
Intervention
Fecal transplantation
Sponsored by
Örebro University, Sweden
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Irritable Bowel Syndrome (IBS) focused on measuring Fecal transplantation, microbiota transplantation, irritable bowel syndrome, IBS

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria for patients

  1. Signed informed consent
  2. Fulfilled Rome III diagnostic criteria for IBS, and frequency of IBS pain or discomfort for at least 2 days a week in the last 12 weeks
  3. Age: 18-65 years

Exclusion criteria for patients

  1. High proportion of butyrate-producing microbiota in fecal samples
  2. Known organic gastrointestinal disease (e.g. IBD)
  3. Previous complicated gastrointestinal surgery
  4. Non-gastrointestinal malignancy
  5. Dementia, severe depression, major psychiatric disorder, or other incapacity for adequate cooperation
  6. Females who are pregnant or breast-feeding
  7. Severe endometriosis
  8. Antimicrobial treatment 4 weeks prior to first screening visit
  9. Antimicrobial prophylaxis (eg. acne, urinary tract infection)
  10. Regular consumption of probiotic products 4 weeks prior to randomization
  11. Recently (within the last 3 months) diagnosed lactose intolerance
  12. Celiac disease
  13. Abuse of alcohol or drugs
  14. Any clinically significant disease/condition which in the investigator's opinion could interfere with the results of the trial

Inclusion criteria for donors

  1. Signed informed consent
  2. High-butyrate producing microbiota in fecal samples
  3. Age: 18-65 years

Exclusion criteria for donors

  1. Known organic gastrointestinal disease (e.g. IBD, IBS, chronic diarrhea or constipation)
  2. Gastrointestinal malignancy or polyposis
  3. History of major gastrointestinal surgery (e.g. gastric bypass)
  4. Eosinophilic disorders of the gastrointestinal tract
  5. Current communicable disease (e.g. upper respiratory tract infection)
  6. Known or high risk of infectious diseases such as HIV, hepatitis A, B or C
  7. Non-gastrointestinal malignancy
  8. Dementia, severe depression, major psychiatric disorder, or other incapacity for adequate cooperation
  9. Comorbidities such as metabolic syndrome, autoimmune diseases, allergies
  10. Chronic pain syndromes (eg. chronic fatigue syndrome, fibromyalgia)
  11. Severe or morbid obesity
  12. Use of immunosuppressive or chemotherapy agents
  13. Antimicrobial treatment or prophylaxis within the last 6 months
  14. Females who are pregnant or breast-feeding
  15. Known clinically significant abnormal laboratory values
  16. Participation in high-risk sexual behaviors
  17. Abuse of alcohol or drugs
  18. Tattoo or body piercing within the last 6 months
  19. Travel to areas with endemic diarrhea during the last 3 months
  20. Positive stool testing for C. difficile toxin, ova, parasites, Giarda antigen, cryptosporidium antigen

Sites / Locations

  • University Hospital Örebro

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Experimental

Arm Label

Fecal transplantation of own stool

Fecal transplantation (stool from donor)

Arm Description

Autologous fecal transplantation (own stool)

Allogeneic fecal transplantation (from donor)

Outcomes

Primary Outcome Measures

Effect of fecal microbiota transplantation on the symptoms of IBS patients using the IBS version of the gastrointestinal symptom rating scale (GSRS-IBS)

Secondary Outcome Measures

Effect of fecal transplantation on IBS patients' visceral perception (Pain scores on the visual analogue scale during barostat procedure)
Effect of fecal transplantation on IBS patients' composition of mucosal microbiota (HITChip analysis)
Effect of fecal transplantation on IBS patients' composition of fecal microbiota (HITChip analysis)
Effect of fecal transplantation on IBS patients' mucosal immune cell composition (lymphocyte fingerprinting using flow cytometry)
Effect of fecal microbiota transplantation on the symptoms of IBS patients using the IBS - severity scoring system (IBS-SSS)
Effect of fecal microbiota transplantation on the symptoms of IBS patients using the health-related quality of life questionnaire for IBS patients (IBS-QOL)
Effect of fecal microbiota transplantation on the symptoms of IBS patients using the hospital and anxiety depression scale (HADS)
Effect of fecal microbiota transplantation on the general health of IBS patients using the SF-36 survey

Full Information

First Posted
March 17, 2014
Last Updated
August 27, 2019
Sponsor
Örebro University, Sweden
search

1. Study Identification

Unique Protocol Identification Number
NCT02092402
Brief Title
Fecal Microbiota Transplantation in Patients With Irritable Bowel Syndrome
Official Title
Fecal Microbiota Transplantation in Patients With Irritable Bowel Syndrome
Study Type
Interventional

2. Study Status

Record Verification Date
August 2019
Overall Recruitment Status
Completed
Study Start Date
September 2013 (undefined)
Primary Completion Date
November 2016 (Actual)
Study Completion Date
June 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Örebro University, Sweden

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to investigate the effect of fecal microbiota transplantation (FMT) on the symptoms of irritable bowel syndrome (IBS) patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Irritable Bowel Syndrome (IBS)
Keywords
Fecal transplantation, microbiota transplantation, irritable bowel syndrome, IBS

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
17 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Fecal transplantation of own stool
Arm Type
Placebo Comparator
Arm Description
Autologous fecal transplantation (own stool)
Arm Title
Fecal transplantation (stool from donor)
Arm Type
Experimental
Arm Description
Allogeneic fecal transplantation (from donor)
Intervention Type
Other
Intervention Name(s)
Fecal transplantation
Primary Outcome Measure Information:
Title
Effect of fecal microbiota transplantation on the symptoms of IBS patients using the IBS version of the gastrointestinal symptom rating scale (GSRS-IBS)
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Effect of fecal transplantation on IBS patients' visceral perception (Pain scores on the visual analogue scale during barostat procedure)
Time Frame
2 months
Title
Effect of fecal transplantation on IBS patients' composition of mucosal microbiota (HITChip analysis)
Time Frame
2 months
Title
Effect of fecal transplantation on IBS patients' composition of fecal microbiota (HITChip analysis)
Time Frame
6 months
Title
Effect of fecal transplantation on IBS patients' mucosal immune cell composition (lymphocyte fingerprinting using flow cytometry)
Time Frame
2 months
Title
Effect of fecal microbiota transplantation on the symptoms of IBS patients using the IBS - severity scoring system (IBS-SSS)
Time Frame
6 months
Title
Effect of fecal microbiota transplantation on the symptoms of IBS patients using the health-related quality of life questionnaire for IBS patients (IBS-QOL)
Time Frame
6 months
Title
Effect of fecal microbiota transplantation on the symptoms of IBS patients using the hospital and anxiety depression scale (HADS)
Time Frame
6 months
Title
Effect of fecal microbiota transplantation on the general health of IBS patients using the SF-36 survey
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria for patients Signed informed consent Fulfilled Rome III diagnostic criteria for IBS, and frequency of IBS pain or discomfort for at least 2 days a week in the last 12 weeks Age: 18-65 years Exclusion criteria for patients High proportion of butyrate-producing microbiota in fecal samples Known organic gastrointestinal disease (e.g. IBD) Previous complicated gastrointestinal surgery Non-gastrointestinal malignancy Dementia, severe depression, major psychiatric disorder, or other incapacity for adequate cooperation Females who are pregnant or breast-feeding Severe endometriosis Antimicrobial treatment 4 weeks prior to first screening visit Antimicrobial prophylaxis (eg. acne, urinary tract infection) Regular consumption of probiotic products 4 weeks prior to randomization Recently (within the last 3 months) diagnosed lactose intolerance Celiac disease Abuse of alcohol or drugs Any clinically significant disease/condition which in the investigator's opinion could interfere with the results of the trial Inclusion criteria for donors Signed informed consent High-butyrate producing microbiota in fecal samples Age: 18-65 years Exclusion criteria for donors Known organic gastrointestinal disease (e.g. IBD, IBS, chronic diarrhea or constipation) Gastrointestinal malignancy or polyposis History of major gastrointestinal surgery (e.g. gastric bypass) Eosinophilic disorders of the gastrointestinal tract Current communicable disease (e.g. upper respiratory tract infection) Known or high risk of infectious diseases such as HIV, hepatitis A, B or C Non-gastrointestinal malignancy Dementia, severe depression, major psychiatric disorder, or other incapacity for adequate cooperation Comorbidities such as metabolic syndrome, autoimmune diseases, allergies Chronic pain syndromes (eg. chronic fatigue syndrome, fibromyalgia) Severe or morbid obesity Use of immunosuppressive or chemotherapy agents Antimicrobial treatment or prophylaxis within the last 6 months Females who are pregnant or breast-feeding Known clinically significant abnormal laboratory values Participation in high-risk sexual behaviors Abuse of alcohol or drugs Tattoo or body piercing within the last 6 months Travel to areas with endemic diarrhea during the last 3 months Positive stool testing for C. difficile toxin, ova, parasites, Giarda antigen, cryptosporidium antigen
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Robert J Brummer, MD, PhD
Organizational Affiliation
University Hospital Örebro, Department of Gastroenterology and Örebro University, School of Health and Medical Sciences, Faculty of Medicine and Health, Örebro, Sweden
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospital Örebro
City
Örebro
ZIP/Postal Code
70185
Country
Sweden

12. IPD Sharing Statement

Learn more about this trial

Fecal Microbiota Transplantation in Patients With Irritable Bowel Syndrome

We'll reach out to this number within 24 hrs